Patents by Inventor Matthew L. Del Bel

Matthew L. Del Bel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Azalactam compounds as HPK1 inhibitors
    Patent number: 11684616
    Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: June 27, 2023
    Assignee: PFIZER INC.
    Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
  • Azalactam Compounds as HPK1 Inhibitors
    Publication number: 20220401424
    Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: April 30, 2021
    Publication date: December 22, 2022
    Applicant: PFIZER INC.
    Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
  • Azalactam compounds as HPK1 inhibitors
    Patent number: 11142525
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: October 12, 2021
    Assignee: PFIZER INC.
    Inventors: Rebecca Anne Gallego, Sajiv Krishnan Nair, Robert Steven Kania, Omar Khaled Ahmad, Ted William Johnson, Jamison Bryce Tuttle, Mehran Jalaie, Michele Ann McTigue, Dahui Zhou, Matthew L. Del Bel, Ru Zhou, Mingying He, Anne-Marie Dechert Schmitt
  • Azalactam Compounds as HPK1 Inhibitors
    Publication number: 20200172539
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: November 11, 2019
    Publication date: June 4, 2020
    Applicant: Pfizer Inc.
    Inventors: Rebecca Anne Gallego, Sajiv Krishnan Nair, Robert Steven Kania, Omar Khaled Ahmad, Ted William Johnson, Jamison Bryce Tuttle, Mehran Jalaie, Michele Ann McTigue, Dahui Zhou, Matthew L. Del Bel, Ru Zhou, Mingying He